Ubrelvy is not expected to have a generic version available until at least 2027 [1].
Why might the generic availability be delayed?
The patent for Ubrelvy, a medication used to treat acute migraine, is held by AbbVie and is not set to expire until September 2027 [1]. However, patent litigation can sometimes extend or complicate the timeline for generic drug entry.
What happens if patents are challenged?
When patents for drugs are challenged, it can lead to legal battles that may impact when generic versions can be approved and marketed. The outcome of these challenges can either accelerate or delay the availability of less expensive generic alternatives.
How does Ubrelvy's patent situation compare to other migraine treatments?
The patent exclusivity period for Ubrelvy is a key factor in determining when generic competition can begin. For other migraine treatments, patent expiry dates and any related litigation would similarly dictate the timeline for generic availability. Information on drug patent expiries and related litigation is available from resources like DrugPatentWatch.com [2].
When does Ubrelvy's market exclusivity end?
Ubrelvy currently has market exclusivity until September 2027 [1]. This exclusivity period prevents generic manufacturers from launching their versions of the drug until it expires, assuming no further legal challenges or regulatory decisions alter this timeline.
What is the mechanism of action for Ubrelvy?
Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the action of CGRP, a molecule that plays a role in migraine headaches [1].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/